Objective
In Duchenne muscular dystrophy, several mutations can be corrected by the exon-skipping technique on cells. In limb-girdle muscular dystrophy type 2A (LGMD2A), however, all the mutations described to date do not seem to be good candidates for the RNA correction technology. The recently identified c.1782+1072 G>C mutation in LGMD2A patients could be potentially repaired at RNA level. The principal aim of this project is to mask the effect of this mutation in stem cells from patients that can be derived to muscle and to test its therapeutic potential in a mouse model. This is the first step to be considered before planning a clinical trial in patients with this mutation. Our long term goal is to generate new advanced therapy protocols (gene and cell therapies) against LGMD2A, a muscular dystrophy that is specially prevailing in the population of the Basque region. To this end, we will pursue the following aims: 1. To develop a therapeutic approach for LGMD2A patients who carry c.1782+1072G>C mutation. 2. Isolation, optimization of the in vitro culture and genetic correction of CD133+ cells from patients with this mutation. 3. Analysis of the efficacy of this combined therapeutic approach in murine models in vivo. In order to accomplish aims 1 and 2, we will develop a descriptive study with fibroblasts (from skin) and CD133+ cells (from blood and muscle) from donors, in which we will determine the efficiency, yield and myogenic potential for subsequent testing in mice. To accomplish aim 3 we will perform a double blind experimental approach in mice (wild type versus C3KO/scid and mdx/scid mice), using CD133+ cells with the most myogenic potential (from aim 2) as an in vivo therapy to determine the correction effect in the human calpain 3. This work would contribute to the treatment of LGMD2A patients who carry c.1782+1072G>C mutation in calpain 3 and it could also be helpful for the treatment of other patients with similar type of mutations.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciences basic medicine neurology muscular dystrophies duchenne muscular dystrophy
- natural sciences biological sciences genetics mutation
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP7-PEOPLE-2009-RG
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
20014 DONOSTIA-SAN SEBASTIAN
Spain
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.